Literature DB >> 21546088

Complement in the brain.

Robert Veerhuis1, Henrietta M Nielsen, Andrea J Tenner.   

Abstract

The brain is considered to be an immune privileged site, because the blood-brain barrier limits entry of blood borne cells and proteins into the central nervous system (CNS). As a result, the detection and clearance of invading microorganisms and senescent cells as well as surplus neurotransmitters, aged and glycated proteins, in order to maintain a healthy environment for neuronal and glial cells, is largely confined to the innate immune system. In recent years it has become clear that many factors of innate immunity are expressed throughout the brain. Neuronal and glial cells express Toll like receptors as well as complement receptors, and virtually all complement components can be locally produced in the brain, often in response to injury or developmental cues. However, as inflammatory reactions could interfere with proper functioning of the brain, tight and fine tuned regulatory mechanisms are warranted. In age related diseases, such as Alzheimer's disease (AD), accumulating amyloid proteins elicit complement activation and a local, chronic inflammatory response that leads to attraction and activation of glial cells that, under such activation conditions, can produce neurotoxic substances, including pro-inflammatory cytokines and oxygen radicals. This process may be exacerbated by a disturbed balance between complement activators and complement regulatory proteins such as occurs in AD, as the local synthesis of these proteins is differentially regulated by pro-inflammatory cytokines. Much knowledge about the role of complement in neurodegenerative diseases has been derived from animal studies with transgenic overexpressing or knockout mice for specific complement factors or receptors. These studies have provided insight into the potential therapeutic use of complement regulators and complement receptor antagonists in chronic neurodegenerative diseases as well as in acute conditions, such as stroke. Interestingly, recent animal studies have also indicated that complement activation products are involved in brain development and synapse formation. Not only are these findings important for the understanding of how brain development and neural network formation is organized, it may also give insights into the role of complement in processes of neurodegeneration and neuroprotection in the injured or aged and diseased adult central nervous system, and thus aid in identifying novel and specific targets for therapeutic intervention.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546088      PMCID: PMC3142281          DOI: 10.1016/j.molimm.2011.04.003

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  179 in total

1.  Immunopathology of secondary-progressive multiple sclerosis.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

Review 2.  Cbln and C1q family proteins: new transneuronal cytokines.

Authors:  M Yuzaki
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

4.  Human brain pericytes as a model system to study the pathogenesis of cerebrovascular amyloidosis in Alzheimer's disease.

Authors:  M M Verbeek; I Otte-Höller; D J Ruiter; R M de Waal
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1999-02       Impact factor: 1.770

5.  Activated microglial cells and complement factors are unrelated to cortical Lewy bodies.

Authors:  A J Rozemuller; P Eikelenboom; J W Theeuwes; E N Jansen Steur; R A de Vos
Journal:  Acta Neuropathol       Date:  2000-12       Impact factor: 17.088

6.  Complement activation in very early Alzheimer disease.

Authors:  H Zanjani; C E Finch; C Kemper; J Atkinson; D McKeel; J C Morris; J L Price
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Apr-Jun       Impact factor: 2.703

7.  Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease.

Authors:  Malabendu Jana; Carlos A Palencia; Kalipada Pahan
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Functional and structural similarities between protease nexin I and C1 inhibitor.

Authors:  W E Van Nostrand; L D McKay; J B Baker; D D Cunningham
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

9.  C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production.

Authors:  Deborah A Fraser; Karntipa Pisalyaput; Andrea J Tenner
Journal:  J Neurochem       Date:  2009-11-16       Impact factor: 5.372

10.  Expression of innate immune complement regulators on brain epithelial cells during human bacterial meningitis.

Authors:  Cecile Canova; Jim W Neal; Philippe Gasque
Journal:  J Neuroinflammation       Date:  2006-09-02       Impact factor: 8.322

View more
  162 in total

1.  Mannose-binding lectin-the forgotten molecule?

Authors:  Michael Osthoff; George Trendelenburg; Damon P Eisen; Marten Trendelenburg
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

2.  Stress-Induced Alterations of Immune Profile in Animals Suffering by Tau Protein-Driven Neurodegeneration.

Authors:  Petr Novak; Martin Cente; Nina Kosikova; Tomas Augustin; Richard Kvetnansky; Michal Novak; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2017-04-12       Impact factor: 5.046

Review 3.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 4.  The Role of Complement C3a Receptor in Stroke.

Authors:  Saif Ahmad; Kanchan Bhatia; Adam Kindelin; Andrew F Ducruet
Journal:  Neuromolecular Med       Date:  2019-05-17       Impact factor: 3.843

5.  C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.

Authors:  Christian S Lobsiger; Severine Boillée; Christine Pozniak; Amir M Khan; Melissa McAlonis-Downes; Joseph W Lewcock; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

6.  Synaptic and complement markers in extracellular vesicles in multiple sclerosis.

Authors:  Pavan Bhargava; Carlos Nogueras-Ortiz; Sol Kim; Francheska Delgado-Peraza; Peter A Calabresi; Dimitrios Kapogiannis
Journal:  Mult Scler       Date:  2020-06-17       Impact factor: 6.312

7.  Fosb gene products contribute to excitotoxic microglial activation by regulating the expression of complement C5a receptors in microglia.

Authors:  Hiroko Nomaru; Kunihiko Sakumi; Atsuhisa Katogi; Yoshinori N Ohnishi; Kosuke Kajitani; Daisuke Tsuchimoto; Eric J Nestler; Yusaku Nakabeppu
Journal:  Glia       Date:  2014-04-25       Impact factor: 7.452

8.  Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.

Authors:  Qiaoqiao Shi; Saba Chowdhury; Rong Ma; Kevin X Le; Soyon Hong; Barbara J Caldarone; Beth Stevens; Cynthia A Lemere
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

9.  Innate immune network in the retina activated by optic nerve crush.

Authors:  Justin P Templeton; Natalie E Freeman; John M Nickerson; Monica M Jablonski; Tonia S Rex; Robert W Williams; Eldon E Geisert
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-09       Impact factor: 4.799

Review 10.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.